New diet pill no easy path to weight loss
Experts are skeptical that Belviq, the first weight-loss treatment approved by the FDA in more than a decade, is worth the bother.
For one thing, Belviq has a host of side effects ranging from dizziness to heart valve problems to painful erections. To make matters worse, patients have to take Belviq for the rest of their lives and it carries a hefty wholesale price of $200 per month. The results achieved by Belviq, which the FDA has approved for adults who are overweight and also suffer from diabetes or other serious medical conditions, are nothing special either.
"In a study, the average weight loss over the course of a year using Belviq was 3.7% more of a person’s total body weight than the patients on placebo," according to The Los Angeles Times, adding that's a loss of fewer than 10 pounds for a 250-pound person. "That sort of loss could be easily achieved by mild changes in eating and exercise habits."
Consumer Reports, which is advising people to take a pass on Belviq, said patients in one trial lost up to 5% of their body weight after 12 months but regained 25% of it by the end of the second year.
For its part, Arena said Belviq has been proven to be safe and effective.
The costs associated with obesity are astounding, some $190 billion a year, or more than 20% of U.S. health care expenditures.
Unfortunately, for many there are no shortcuts to losing weight.
--Jonathan Berr does not own shares of the listed stocks. Follow him on Twitter @jdberr.
- How the Affordable Care Act becomes unaffordable
- Showdown looms over 'bring your guns to work' laws
- DirecTV gets burned over Colorado fire fees
This author needs to go back and read the specs from the FDA label, Jonathon Berr is 100% inaccurate on this piece. Also, he needs to read what the American Association of Clinical Endocrinology endorsement says about new "novel" weight lose medication options.
Oh, did I mention that Belviq is a new "Novel" Rx. The first new "Novel" Obesity Rx approved in 13 years, with "No' REMS.
what an ignorant statement. The FDA determined Belviq to be safe and effective.
8% completer efficacy / 12% responder efficacy in a year - excellent safety profile. Poor short sellers. No article is going to help them.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
[BRIEFING.COM] The stock market finished an upbeat week on a mixed note. The S&P 500 added just over a point, holding its weekly gain at 1.0% while the Nasdaq lost 0.4%.
The major averages began the day on an upbeat note, but relinquished their opening gains during the first 90 minutes of action. The early sentiment was boosted by a better-than-expected nonfarm payrolls report for February (175K versus Briefing.com consensus 163K), but a closer look into the report suggested that ... More
More Market News
The solid report comes a month after the retailer closed all of its Canadian operations.
MUST-SEE ON MSN
- Video: Easy DIY smoked meats at home
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'